Research & development increased 12.4%
Research & development changed +12.4% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development changed +12.4% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Working capital / assets changed +194 basis points from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Cash & equivalents changed +10.2% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Operating cash flow changed -2.1% from the comparable as-filed period.
Current ratio changed -10.6% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Current assets changed +7.5% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Stock-based compensation changed -4.2% from the comparable as-filed period.
Total assets changed -1.6% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
Working capital changed +2.3% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.